The ODYSSEY DM-DYSLIPIDEMIA trial: Confirming the benefits of alirocumab in diabetic mixed dyslipidemia

Paul Chan, Li Shao, Brian Tomlinson, Zhong Min Liu

研究成果: 雜誌貢獻 › 社論 › 同行評審

原文	英語
文章編號	477
期刊	Annals of Translational Medicine
卷	5
發行號	23
DOIs	https://doi.org/10.21037/atm.2017.10.26
出版狀態	已發佈 - 12月 2017

ASJC Scopus subject areas

此研究成果有助於以下永續發展目標

@article{0572c1e58f524b338d5f7c0cd122b1d3,

title = "The ODYSSEY DM-DYSLIPIDEMIA trial: Confirming the benefits of alirocumab in diabetic mixed dyslipidemia",

author = "Paul Chan and Li Shao and Brian Tomlinson and Liu, {Zhong Min}",

year = "2017",

month = dec,

doi = "10.21037/atm.2017.10.26",

language = "English",

volume = "5",

journal = "Annals of Translational Medicine",

issn = "2305-5839",

publisher = "AME Publishing Company",

number = "23",

}

TY - JOUR

T1 - The ODYSSEY DM-DYSLIPIDEMIA trial

T2 - Confirming the benefits of alirocumab in diabetic mixed dyslipidemia

AU - Chan, Paul

AU - Shao, Li

AU - Tomlinson, Brian

AU - Liu, Zhong Min

PY - 2017/12

Y1 - 2017/12

UR - http://www.scopus.com/inward/record.url?scp=85037134727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037134727&partnerID=8YFLogxK

U2 - 10.21037/atm.2017.10.26

DO - 10.21037/atm.2017.10.26

M3 - Editorial

AN - SCOPUS:85037134727

VL - 5

JO - Annals of Translational Medicine

JF - Annals of Translational Medicine

SN - 2305-5839

IS - 23

M1 - 477

ER -